Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results.
Hagen F KenneckeChris J O'CallaghanJonathan M LoreeHussein MolooRebecca A C AuerDerek J JonkerManoj J RavalReilly MusselmanGrace MaAntonio Caycedo-MarulandaVlad V SimianuSunil PatelLacey D PitreRamzi HelewaVallerie L GordonKaterina NeumannHalla NimeiriMax SherryDongsheng TuCarl James BrownPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Three months of induction chemotherapy may successfully downstage a significant proportion of patients with early-stage rectal cancer, allowing well-tolerated organ-preserving surgery.
Keyphrases
- locally advanced
- phase ii
- rectal cancer
- neoadjuvant chemotherapy
- early stage
- clinical trial
- open label
- sentinel lymph node
- phase iii
- minimally invasive
- coronary artery bypass
- placebo controlled
- squamous cell carcinoma
- double blind
- radiation therapy
- study protocol
- randomized controlled trial
- percutaneous coronary intervention
- acute coronary syndrome
- atrial fibrillation